BioCentury
ARTICLE | Product R&D

Avidly specific

How AvidBiotics is taking on the microbiome with bactericidal peptides.

October 5, 2017 11:17 PM UTC

With its first two programs headed for the clinic next year, AvidBiotics Corp. is seeing the fruits of its move to human therapeutics from food safety and animal health. Using engineered peptides, the company has built two platforms that give it plays in the ever-growing fields of the microbiome and CAR T cells.

The platforms, dubbed Avidocin and convertibleCAR, share few features, save the use of protein engineering to create compounds that aim to beat the competition on specificity and safety. ...

BCIQ Company Profiles

AvidBiotics Corp.